Drug plus lower-dose radiation for early-stage nasal lymphoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, selinexor, combined with a lower dose of radiation for people with early-stage extranodal NK/T-cell lymphoma that started in the nose or upper throat. The goal is to see if this combination works well and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with extranodal NK/T-cell lymphoma (a rare type of lymphoma) that is in the nose or upper throat and has not spread far (stage I or II).
- You have not had any previous treatment for this lymphoma, such as radiation, chemotherapy, or targeted therapy.
- You are generally in good health, with adequate blood cell counts, liver, kidney, and heart function.
- You do not have other serious infections like active hepatitis B or C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial compares a new targeted drug combined with standard chemotherapy and an immunotherapy drug against the standard chemo-immunotherapy alone, for people with advanced or non-nasal NK/T-cell lymphoma who haven't been treated yet. The goal is to see if adding the targeted drug improves outcomes.
This study tests a new medicine called sugemalimab (an immunotherapy that helps your immune system fight cancer) combined with a chemotherapy regimen (PGemOx) for people with a rare type of lymphoma that has come back or not responded to previous treatment. The study could help you see if this combination works better than the placebo (inactive) plus the same chemotherapy.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This study tests a new combination of medications for people with early-stage nasal natural killer/T-cell lymphoma. The goal is to see if adding a targeted therapy to standard treatment helps control the disease with manageable side effects.
This trial tests a combination of three drugs (selinexor, pegaspargase, and dexamethasone) for people with newly diagnosed NK/T-cell lymphoma. It aims to see if this treatment can shrink tumors and be safe.
Hear when a new Extranodal NK/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.